Life Science Venture Capital

Taro Tanaka serves as Representative Director and President, overseeing all investment decisions. The firm operates as a specialized partnership with Tanaka as the managing principal, reflecting a concentrated decision-making structure common among Japan's boutique venture firms.

The firm leverages deep connections within Japan's university research ecosystem, including relationships with technology licensing offices at institutions such as the University of Tokyo and Osaka University. By targeting the translational gap where academic discoveries struggle to attract generalist venture funding, the firm positions itself as an early gatekeeper for institutional-grade biotech opportunities.

The firm focuses on direct equity investments in operating companies, typically leading or co-leading rounds rather than acting as a fund-of-funds. Syndicates frequently include corporate venture arms from major Japanese pharmaceutical companies seeking external innovation exposure.

The mandate spans the full lifecycle from seed-stage proof-of-concept investments to pre-IPO crossover rounds. This allows the firm to support portfolio companies through multiple financing cycles, a structural advantage in Japan where follow-on capital for life-science ventures is often unpredictable.

The firm maintains a strict life-science mandate and does not invest in general information technology, consumer internet, or industrial sectors. Within healthcare, its known posture avoids pure-play service businesses without a technology or IP component, focusing instead on drug discovery platforms, medical devices, and digital health infrastructure.